Malignancies of the head and neck: the role for molecular targeted agents.

about

Malignancies of the head and neck: the role for molecular targeted agents.

Item

http://www.wikidata.org/entity/Q36709551

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Malignancies of the head and neck: the role for molecular targeted agents.

@ast

Malignancies of the head and neck: the role for molecular targeted agents.

@en

type

Item

label

Malignancies of the head and neck: the role for molecular targeted agents.

@ast

Malignancies of the head and neck: the role for molecular targeted agents.

@en

prefLabel

Malignancies of the head and neck: the role for molecular targeted agents.

@ast

Malignancies of the head and neck: the role for molecular targeted agents.

@en

P1476

Malignancies of the head and neck: the role for molecular targeted agents.

@en

P2093

Mark Agulnik

http://www.w3.org/2001/XMLSchema#string

P2860

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

Cell signaling by receptor tyrosine kinases

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

The epidermal growth factor receptor and its inhibition in cancer therapy.

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

The EGF receptor family as targets for cancer therapy.

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

P304

207-217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.11.2.207

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17227235

http://www.w3.org/2001/XMLSchema#string